Spots Global Cancer Trial Database for infections, papillomavirus
Every month we try and update this database with for infections, papillomavirus cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| The Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study | NCT01249365 | Infections, Pap... | GSK580299 (Cerv... | 26 Years - | GlaxoSmithKline | |
| Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents | NCT00534638 | Infections, Pap... | Cervarix Engerix-B | 12 Years - 15 Years | GlaxoSmithKline | |
| Evaluation of Safety of a Vaccine Against Cervical Cancer in Healthy Korean Females | NCT01101542 | Infections, Pap... | Cervarix. Data collection | 10 Years - 25 Years | GlaxoSmithKline | |
| Extension Study of the Efficacy of the GSK 580299 Vaccine in Japanese Women Vaccinated in the Primary NCT00316693 Study | NCT00929526 | Infections, Pap... | Liquid-based cy... Blood sampling | 20 Years - 25 Years | GlaxoSmithKline | |
| Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects | NCT00652938 | Infections, Pap... | HPV Vaccine (GS... Engerix B | 9 Years - 15 Years | GlaxoSmithKline | |
| Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects | NCT00578227 | Infections, Pap... | Cervarix™ Twinrix ™ Paedi... | 9 Years - 15 Years | GlaxoSmithKline | |
| Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Brazil, Taiwan or Thailand | NCT00849381 | Infections, Pap... | GSK580299, GSK ... | 26 Years - | GlaxoSmithKline | |
| Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Brazil, Taiwan or Thailand | NCT00849381 | Infections, Pap... | GSK580299, GSK ... | 26 Years - | GlaxoSmithKline | |
| Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects | NCT00947115 | Infections, Pap... | Blood sampling Cervico-vaginal... | 20 Years - 60 Years | GlaxoSmithKline | |
| Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls | NCT01381575 | Infections, Pap... | GSK Biologicals... | 9 Years - 25 Years | GlaxoSmithKline | |
| Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females | NCT01031069 | Infections, Pap... Papillomavirus ... | GSK Biologicals... Merck's Human P... | 15 Years - 25 Years | GlaxoSmithKline | |
| Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects | NCT00652938 | Infections, Pap... | HPV Vaccine (GS... Engerix B | 9 Years - 15 Years | GlaxoSmithKline | |
| Type Distribution of Human Papillomavirus in Adult African Women Diagnosed With Invasive Cervical Cancer | NCT01207999 | Infections, Pap... Cervical Cancer | Collection of c... Data collection | 21 Years - | GlaxoSmithKline | |
| Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Brazil, Taiwan or Thailand | NCT00849381 | Infections, Pap... | GSK580299, GSK ... | 26 Years - | GlaxoSmithKline | |
| Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls | NCT01381575 | Infections, Pap... | GSK Biologicals... | 9 Years - 25 Years | GlaxoSmithKline | |
| Study on the Prevalence of Human Papillomavirus Types in Women >= 15 Years of Age in the Kingdom of Saudi Arabia | NCT01213459 | Infections, Pap... Cervical Cancer | Cervical sample... Data collection | 15 Years - | GlaxoSmithKline | |
| Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix) in HIV Infected Females | NCT00586339 | Infections, Pap... | Cervarix Placebo Control | 18 Years - 25 Years | GlaxoSmithKline | |
| Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US | NCT00799825 | Infections, Pap... | GSK Biological'... | 18 Years - | GlaxoSmithKline | |
| Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs | NCT00541970 | Infections, Pap... | Cervarix Placebo | 9 Years - 25 Years | GlaxoSmithKline | |
| Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of Age | NCT00552279 | Infections, Pap... | Cervarix TM Cervarix TM | 15 Years - 25 Years | GlaxoSmithKline | |
| Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18 | NCT00122681 | Infections, Pap... | Cervarix™ Havrix™-based i... | 15 Years - 25 Years | GlaxoSmithKline | |
| Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older | NCT00294047 | Infections, Pap... Papillomavirus ... | Cervarix Placebo control | 26 Years - | GlaxoSmithKline | |
| Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study | NCT01190189 | Infections, Pap... | GSK580299 (Cerv... | 26 Years - | GlaxoSmithKline | |
| Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects | NCT00779766 | Infections, Pap... | HPV GSK 580299 ... Placebo control | 18 Years - 25 Years | GlaxoSmithKline | |
| Safety Evaluation of a Human Papillomavirus (HPV) Vaccine in Healthy Female Control Subjects From the GSK HPV 023 Study | NCT01418937 | Infections, Pap... | CervarixTM (GSK... | 26 Years - | GlaxoSmithKline | |
| Follow-up Study to Evaluate the Safety and Immunogenicity of a HPV Vaccine (580299) in North America | NCT00546078 | Infections, Pap... | Cervarix™ | 15 Years - 25 Years | GlaxoSmithKline | |
| Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects. | NCT00877877 | Infections, Pap... Papillomavirus ... | Blood sampling | 15 Years - 24 Years | GlaxoSmithKline | |
| Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents | NCT00534638 | Infections, Pap... | Cervarix Engerix-B | 12 Years - 15 Years | GlaxoSmithKline | |
| Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18 | NCT00122681 | Infections, Pap... | Cervarix™ Havrix™-based i... | 15 Years - 25 Years | GlaxoSmithKline | |
| Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Brazil, Taiwan or Thailand | NCT00849381 | Infections, Pap... | GSK580299, GSK ... | 26 Years - | GlaxoSmithKline | |
| Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US | NCT00799825 | Infections, Pap... | GSK Biological'... | 18 Years - | GlaxoSmithKline | |
| Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects | NCT00652938 | Infections, Pap... | HPV Vaccine (GS... Engerix B | 9 Years - 15 Years | GlaxoSmithKline | |
| Study on the Prevalence of Human Papillomavirus Types in Women >= 15 Years of Age in the Kingdom of Saudi Arabia | NCT01213459 | Infections, Pap... Cervical Cancer | Cervical sample... Data collection | 15 Years - | GlaxoSmithKline | |
| Study on the Prevalence of Human Papillomavirus Types in Women >= 15 Years of Age in the Kingdom of Saudi Arabia | NCT01213459 | Infections, Pap... Cervical Cancer | Cervical sample... Data collection | 15 Years - | GlaxoSmithKline | |
| Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study | NCT01190189 | Infections, Pap... | GSK580299 (Cerv... | 26 Years - | GlaxoSmithKline | |
| Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs | NCT00541970 | Infections, Pap... | Cervarix Placebo | 9 Years - 25 Years | GlaxoSmithKline |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
